The U.S. dollar index, which tracks the greenback against a basket of six global currency peers, rose 0.7% over the three months ending in September and 1.33% against the European single currency. Today's earnings guidance points to full year earnings in the range of $2.98 to $3.02, a figure that matches the estimate it published alongside its second quarter earnings in July. Breaking down product sales for the quarter shows that Lyrica, is key epilepsy treatment, saw revenues fall 1.5% to $1.132 billion while its blockbuster Prevnar vaccine rose 9% to $1.66 billion. Ibrance, its breast cancer treatment, saw sales rise 16.7% to $1.025 billion.